研究者学術情報データベース

カツラ　トシヤ
桂　敏也
KATSURA TOSHIYA

所属薬学部薬学科

職名教授

論文
1.	2024	Association of direct oral anticoagulant and delayed bleeding with pharmacokinetics after endoscopic submucosal dissection. │ Gastrointestinal Endoscopy │ in press (共著)
2.	2024	Pharmacokinetic properties of CYP3A substrate midazolam associated with xenobiotic-mediated CYP induction in inflammation model mice │ BPB Reports │ in press (共著)
3.	2023/10	Attenuation of phenobarbital-induced cytochrome P450 expression in carbon tetrachloride-induced hepatitis in mice models. │ Biopharmaceutics & Drug Disposition │ 44 (5),351-357頁 (共著)
4.	2023/09/01	聞いてみよう　薬剤師の知りたいこと　いまさら聞けない！？「トランスポーター」 │ 調剤と情報 │ 29 (12),2149-2154頁 (単著)
5.	2023	アピキサバン内服による出血症状の危険因子に関するゲノム薬理学と薬剤疫学の融合研究 │ 臨床薬理の進歩 │ 44,102-109頁 (共著)
6.	2022/09	Decreased serum copper concentrations by zinc administration in preterm infants with hypozincemia are associated with a lower postmenstrual age: A single-center retrospective observational study. │ YAKUGAKU ZASSHI │ 142 (9),999-1004頁 (共著)
7.	2022/07	Changes in the expression of drug-metabolising enzymes and drug transporters in mice with collagen antibody-induced arthritis. │ Xenobiotica │ 52 (7),758-766頁 (共著)
8.	2021/12	Administration of zinc to preterm infants with hypozincemia does not reduce serum copper concentrations in most cases: A single-center retrospective observational study. │ J. Pharm. Health Care Sci. │ 7 (1),46 (共著)
9.	2021/11	Variation in expression of cytochrome P450 3A isoforms and toxicological effects: Endo- and exogenous substances as regulatory factors and substrates. │ Biol. Pharm. Bull. │ 44 (11),1617-1634頁 (共著)
10.	2019/10	Genetic variants of alcohol‐metabolizing enzymes in Brugada syndrome: Insights into syncope after drinking alcohol. │ J. Arrhythmia │ 35 (5),752-759頁 (共著)
11.	2019/09	Population pharmacokinetics and pharmacodynamics of apixaban linking its plasma concentration to intrinsic activated coagulation factor X activity in Japanese patients with atrial fibrillation. │ AAPS J. │ 21 (5),20 (共著)
12.	2018/06	Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. │ Br. J. Clin. Pharmacol. │ 84 (6),1301-1312頁 (共著)
13.	2017/09	Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. │ Pharmacogenet. Genomics │ 27 (9),329-336頁 (共著)
14.	2016/12	オキサリプラチンによるアレルギーで中止後、再投与により薬剤誘発性血小板減少症に至った 1 症例 │ 医療薬学 │ 42 (12),834-838 (共著)
15.	2016/05	Safety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel in patients with critical limb ischemia. │ Heart Vessels │ 31 (5),713-721 (共著)
16.	2015/01	Journal of Pharmaceutical Health Care and Sciences (Editorial) │ J. Pharm. Health Care Sci. │ 1,1 (単著)
17.	2014/06	Sorafenib in a hepatocellular carcinoma patient with end-stage renal failure: A pharmacokinetic study. │ Hepatol. Res. │ 44 (6),685-688 (共著)
18.	2014/06	The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma. │ Ther. Drug Monit. │ 36 (3),310-316 (共著)
19.	2014/03	悪性神経膠腫患者に対するtemozolomide・放射線併用療法における有害反応解析 │ 日本病院薬剤師会雑誌 │ 50 (3),299-304 (共著)
20.	2014/01	Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins. │ Pharm. Res. │ 31 (1),136-147 (共著)
21.	2013/09	Precise comparison of protein localization among OCT, OAT, and MATE in human kidney. │ J. Pharm. Sci. │ 102 (9),3302-3308 (共著)
22.	2013/08	Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats. │ Drug Metab.Dispos. │ 41 (8),1592-1597 (共著)
23.	2013/07	Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. │ Clin. Pharmacokinet. │ 52 (7),593-609 (共著)
24.	2012/12	Detection of 22 antiepileptic drugs by ultra-performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring. │ Biomed. Chromatogr. │ 26 (12),1519-1528 (共著)
25.	2012/12	Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics. │ Drug Metab. Pharmacokinet. │ 27 (6),631-639 (共著)
26.	2012/12	Renal tubular secretion of varenicline by multidrug and toxin extrusion (MATE) transporters. │ Drug Metab. Pharmacokinet. │ 27 (6),563-569 (共著)
27.	2012/09	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. │ Cancer Chemother. Pharmacol. │ 70 (3),399-405 (共著)
28.	2012/08	下痢時の臀部皮膚保護剤としてのCMC含有軟膏の使用経験 │ 皮膚の科学 │ 11 (4),319-322 (共著)
29.	2012/07	治験薬GMPに基づいた臨床試験用院内無菌製剤室の設置と適合性評価 │ 医療薬学 │ 38 (7),423-434 (共著)
30.	2012/06	Developmental expression of renal organic anion transporters in rat kidney and its effect on renal secretion of phenolsulfonphthalein. │ Am. J. Physiol. Renal Physiol. │ 302 (12),F1640-F1649 (共著)
31.	2012/06	Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis. │ Br. J. Pharmacol. │ 166 (3),1183-1191 (共著)
32.	2012/06	ペメトレキセド単独療法の血液毒性に及ぼす腎機能の影響 │ 日本病院薬剤師会雑誌 │ 48 (6),719-723 (共著)
33.	2012/04	オキシコドン併用がワルファリン服用がん患者のプロトロンビン時間に及ぼす影響 │ 医療薬学 │ 38 (4),258-264 (共著)
34.	2012/03	Tacrolimus血中濃度測定法の差異に関する臨床的評価　MEIA、CLIA、ACMIA、EMIT間の比較検討 │ 移植 │ 47 (1),75-81 (共著)
35.	2011/11	進行肝細胞がん患者におけるソラフェニブの服薬継続ならびに有害事象発現に及ぼす影響因子の検討 │ 医療薬学 │ 37 (11),631-636 (共著)
36.	2011/10	Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. │ Cancer Chemother. Pharmacol. │ 68 (4),1089-1092 (共著)
37.	2011/05	Effects of metabolic acidosis on expression levels of renal drug transporters. │ Pharm. Res. │ 28 (5),1023-1030 (共著)
38.	2010/12	Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. │ Biochem. Pharmacol. │ 80 (11),1762-1767 (共著)
39.	2010/12	エルロチニブ服用継続に影響を及ぼす因子の探索 │ 日本病院薬剤師会雑誌 │ 46 (12),1653-1656 (共著)
40.	2010/10	A transient increase of calcineurin phosphatase activity in living-donor kidney transplant recipients with acute rejection. │ Drug Metab. Pharmacokinet. │ 25 (5),411-417 (共著)
41.	2010/08	Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. │ J. Pharmacol. Exp. Ther. │ 334 (2),651-656 (共著)
42.	2010/07	Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain. │ J. Nutr. │ 140 (7),1220-1226 (共著)
43.	2010/06	ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. │ Ann. Oncol. │ 21 (6),1382-1383 (共著)
44.	2010/04	Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. │ Drug Metab. Pharmacokinet. │ 25 (2),190-199 (共著)
45.	2010/02	Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. │ Pharmacogenet. Genomics │ 20 (2),135-138 (共著)
46.	2009/12	Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. │ Biopharm. Drug Dispos. │ 30 (9),517-523 (共著)
47.	2009/11	Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. │ Biochem. Pharmacol. │ 78 (9),1263-1271 (共著)
48.	2009/08	Impact of regulatory polymorphisms in organic anion transporter genes in the human liver. │ Pharmacogenet. Genomics │ 19 (8),647-656 (共著)
49.	2009/07	MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. │ Pharm. Res. │ 26 (7),1590-1595 (共著)
50.	2009/07	Prospective evaluation of the bayesian method for individualizing tacrolimus dose early after living-donor liver transplantation. │ J. Clin. Pharmacol. │ 49 (7),789-797 (共著)
51.	2009/06	Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secretion of metformin. │ Mol. Pharmacol. │ 75 (6),1280-1286 (共著)
52.	2009/04	Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. │ Drug Metab. Dispos. │ 37 (4),821-826 (共著)
53.	2009/04	Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. │ J. Pharmacol. Exp. Ther. │ 329 (1),185-191 (共著)
54.	2009/04	Larger dosage required for everolimus than sirolimus to maintain same blood concentration in two pancreatic islet transplant patients with tacrolimus. │ Drug Metab. Pharmacokinet. │ 24 (2),175-179 (共著)
55.	2009/04	Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. │ Biochem. Pharmacol. │ 77 (8),1429-1436 (共著)
56.	2009/04	UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. │ Int. J. Clin. Oncol. │ 14 (2),136-142 (共著)
57.	2009/03	新規抗悪性腫瘍薬テモゾロミドのカプセル開封後の溶液中での安定性に関する評価 │ 薬学雑誌 │ 129 (3),353-357 (共著)
58.	2009/01	A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. │ Biol. Pharm. Bull. │ 32 (1),99-104 (共著)
59.	2009/01	Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. │ J. Hum. Genet. │ 54 (1),40-46 (共著)
60.	2009/01	乳がん化学療法FEC100におけるG-CSF製剤の使用評価 │ 医療薬学 │ 35 (1),31-36 (共著)
61.	2008/12	Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. │ Drug Metab. Pharmacokinet. │ 23 (6),469-475 (共著)
62.	2008/12	Inhibitory effect of zinc on the absorption of beta-lactam antibiotic ceftibuten via the peptide transporters in rats. │ Drug Metab. Pharmacokinet. │ 23 (6),464-468 (共著)
63.	2008/12	Regulation of basal core promoter activity of human organic cation transporter 1 (OCT1/SLC22A1). │ Am. J. Physiol. Gastrointest. Liver Physiol. │ 295 (6),G1211-G1216 (共著)
64.	2008/11	Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. │ Drug Metab. Dispos. │ 36 (11),2299-2306 (共著)
65.	2008/10	Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile. │ Drug Metab. Pharmacokinet. │ 23 (5),313-317 (共著)
66.	2008/10	Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. │ Biochem. Pharmacol. │ 76 (7),894-903 (共著)
67.	2008/10	外来化学療法における携帯型持続注入器の精度調査 │ 日本病院薬剤師会雑誌 │ 44 (10),1507-1510 (共著)
68.	2008/09	Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. │ Am. J. Physiol. Cell Physiol. │ 295 (3),C632-C641 (共著)
69.	2008/08	Regulatory mechanism governing the diurnal rhythm of intestinal H+/peptide cotransporter 1 (PEPT1). │ Am. J. Physiol. Gastrointest. Liver Physiol. │ 295 (2),G395-G402 (共著)
70.	2008/08	がん化学療法による悪心・嘔吐発現の性差 │ 医療薬学 │ 34 (8),742-747 (共著)
71.	2008/07	Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. │ Am. J. Physiol. Renal Physiol. │ 295 (1),F247-F252 (共著)
72.	2008/07	Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. │ J. Hum. Genet. │ 53 (7),607-614 (共著)
73.	2008/07	Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation. │ Am. J. Physiol. Renal Physiol. │ 295 (1),F165-F170 (共著)
74.	2008/05	Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. │ Pharmacogenet. Genomics │ 18 (5),413-423 (共著)
75.	2008/05	Thyroid hormone regulates the expression and function of P-glycoprotein in Caco-2 cells. │ Pharm. Res. │ 25 (5),1037-1042 (共著)
76.	2008/04	Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. │ Drug Metab. Pharmacokinet. │ 23 (2),134-138 (共著)
77.	2008/03	肺がん患者に対する塩酸アムルビシンの外来化学療法における使用実態調査と血液毒性の評価 │ 医療薬学 │ 34 (3),268-273 (共著)
78.	2007/12	Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. │ Drug Metab. Pharmacokinet. │ 22 (6),441-444 (共著)
79.	2007/11	Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporters (MATE1). │ Am. J. Physiol. Renal Physiol. │ 293 (5),F1564-F1570 (共著)
80.	2007/08	Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. │ Biochem. Pharmacol. │ 74 (3),477-487 (共著)
81.	2007/07	Cl- -dependent upregulation of human organic anion transporters: different effects on transport kinetics between hOAT1 and hOAT3. │ Am. J. Physiol. Renal Physiol. │ 293 (1),F391-F397 (共著)
82.	2007/07	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters. │ Biochem. Pharmacol. │ 74 (2),359-371 (共著)
83.	2007/06	Hepatocyte nuclear factor-4alpha regulates the human organic anion transporter 1 gene in the kidney. │ Am. J. Physiol. Renal Physiol. │ 292 (6),F1819-F1826 (共著)
84.	2007/06	Identification of essential histidine and cysteine residues of the H+/organic cation antiporter multidrug and toxin extrusion (MATE). │ Mol. Pharmacol. │ 71 (6),1487-1493 (共著)
85.	2007/06	Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. │ Biochem. Pharmacol. │ 74 (1),161-168 (共著)
86.	2007/05	Characterization of the basal promoter element of human organic cation transporter 2 gene. │ J. Pharmacol. Exp. Ther. │ 321 (1),684-689 (共著)
87.	2007/05	Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in chronic renal failure rats. │ Biochem. Pharmacol. │ 73 (9),1482-1490 (共著)
88.	2007/04	Is MIBG a substrate of P-glycoprotein? │ Eur. J. Nucl. Med. Mol. Imaging │ 34 (4),448-452 (共著)
89.	2007/04	Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). │ Pharm. Res. │ 24 (4),811-815 (共著)
90.	2007/02	Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1. │ Am. J. Physiol. Renal Physiol. │ 292 (2),F593-F598 (共著)
91.	2007/01	非小細胞肺がん患者に対するゲフィチニブ服用開始時の患者教育システム構築の試み │ 医療薬学 │ 33 (1),1-7 (共著)
92.	2006/12	Temporal decline in sirolimus elimination immediately after pancreatic islet transplantation. │ Drug Metab. Pharmacokinet. │ 21 (6),492-500 (共著)
93.	2006/11	Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). │ J. Pharmacol. Exp. Ther. │ 319 (2),879-886 (共著)
94.	2006/11	Induction of the intestinal peptide transporter 1 expression during fasting is mediated via peroxisome proliferator-activated receptor alpha. │ Am. J. Physiol. Gastrointest. Liver Physiol. │ 291 (5),G851-G856 (共著)
95.	2006/10	Human organic anion transporter 3 gene is regulated constitutively and inducibly via a cAMP responsive element. │ J. Pharmacol. Exp. Ther. │ 319 (1),317-322 (共著)
96.	2006/10	Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. │ Clin. Pharmacol. Ther. │ 80 (4),331-345 (共著)
97.	2006/08	Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. │ J. Am. Soc. Nephrol. │ 17 (8),2127-2135 (共著)
98.	2006/08	Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. │ Pharm. Res. │ 23 (8),1696-1701 (共著)
99.	2006/07	Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer. │ Biol. Pharm. Bull. │ 29 (7),1441-1444 (共著)
100.	2006/07	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. │ J. Pharmacol. Exp. Ther. │ 318 (1),455-460 (共著)
101.	2006/07	癌化学療法の副作用情報統合を目的としたデータシートの構築　−抗腫瘍剤・インターフェロン・放射線併用療法の副作用情報統合と評価− │ 医療薬学 │ 32 (7),599-606 (共著)
102.	2006/05	The transcription factor Cdx2 regulates the intestine-specific expression of human peptide transporter 1 through functional interaction with Sp1. │ Biochem Pharmacol. │ 71 (11),1581-1588 (共著)
103.	2006/04	Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3. │ Pharm. Res. │ 23 (4),697-704 (共著)
104.	2006/04	Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient. │ Drug Metab. Pharmacokinet. │ 21 (2),122-125 (共著)
105.	2006/04	Prediction of glycylsarcosine transport in Caco-2 cell lines expressing PEPT1 at different levels. │ Pflügers Arch. │ 452 (1),64-70 (共著)
106.	2006/04	外来化学療法レジメンの登録と処方支援機能の有用性 │ 医療薬学 │ 32 (4),327-333 (共著)
107.	2006/03	Repeated intravenous injection of recombinant human hepatocyte growth factor ameliorates liver cirrhosis but causes albuminuria in rats. │ Int. J. Mol. Med. │ 17 (3),503-509 (共著)
108.	2006/02	Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: Twice daily vs. once daily dosing. │ Liver Transpl. │ 12 (2),292-300 (共著)
109.	2006/02	Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. │ Pharmacogenet. Genomics │ 16 (2),119-127 (共著)
110.	2006/01	全診療科を対象とした「がん化学療法説明書」の作成とその運用 │ 日本病院薬剤師会雑誌 │ 42 (1),49-52 (共著)
111.	2005/12	Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. │ Biochem. Pharmacol. │ 70 (12),1823-1831 (共著)
112.	2005/12	Expression profiles of various transporters for oligopeptides, amino acids and organic ions along the human digestive tract. │ Biochem. Pharmacol. │ 70 (12),1756-1763 (共著)
113.	2005/12	Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis. │ Pharm. Res. │ 22 (12),2016-2022 (共著)
114.	2005/11	Modulation of P-glycoprotein expression in hyperthyroid rat tissues. │ Drug Metab. Dispos. │ 33 (11),1584-1587 (共著)
115.	2005/10	Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. │ Biochem. Pharmacol. │ 70 (7),1104-1113 (共著)
116.	2005/10	Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. │ Drug Metab. Pharmacokinet. │ 20 (5),379-386 (共著)
117.	2005/09	Characterization of the human peptide transporter PEPT1 promoter: Sp1 functions as a basal transcriptional regulator of human PEPT1. │ Am. J. Physiol. Gastrointest. Liver Physiol. │ 289 (3),G471-G477 (共著)
118.	2005/08	Pharmacodynamic analysis of tacrolimus and cyclosporine in patients of living-donor liver transplantation. │ Clin. Pharmacol. Ther. │ 78 (2),168-181 (共著)
119.	2005/06	Computational modelling of H+-coupled peptide transport via human PEPT1. │ J. Physiol. │ 565 (Pt 2),429-439 (共著)
120.	2005/06	Transcellular transport of creatinine in renal tubular epithelial cell line LLC-PK1. │ Drug Metab. Pharmacokinet. │ 20 (3),200-205 (共著)
121.	2004/06	Decreased activity and expression of intestinal oligopeptide transporter PEPT1 in rats with hyperthyroidism in vivo. │ Pharm. Res. │ 21 (6),969-975 (共著)
122.	2003/09	Inhibitory effect of zinc on PEPT1-mediated transport of glycylsarcosine and beta-lactam antibiotics in human intestinal cell line Caco-2. │ Pharm. Res. │ 20 (9),1389-1393 (共著)
123.	2003/02	Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation. │ Drug Metab. Pharmacokinet. │ 18 (1),1-15 (共著)
124.	2002/04	Thyroid hormone regulates the activity and expression of the peptide transporter PEPT1 in Caco-2 cells. │ Am. J. Physiol. Gastrointest. Liver Physiol. │ 282 (4),G617-G623 (共著)
125.	2001/08	Expression of peptide transporter following intestinal transplantation in the rat. │ J. Surg. Res. │ 99 (2),294-300 (共著)
126.	2001/05	Effects of tacrolimus and cyclosporin A on peptide transporter PEPT1 in Caco-2 cells. │ Pharm. Res. │ 18 (5),713-717 (共著)
127.	2001/05	Transport of levofloxacin in the OK kidney epithelial cell line: Interaction with p-aminohippurate transport. │ Pharm. Res. │ 18 (5),573-578 (共著)
128.	2000/10	Transport of procainamide via H+/tertiary amine antiport system in rabbit intestinal brush-border membrane. │ Am. J. Physiol. Gastrointest. Liver Physiol. │ 279 (4),G799-G805 (共著)
129.	2000/05	Transepithelial transport of diphenhydramine across monolayers of the human intestinal epithelial cell line Caco-2. │ Pharm. Res. │ 17 (5),539-545 (共著)
130.	2000/04	Diphenhydramine transport by pH-dependent tertiary amine transport system in Caco-2 cells. │ Am. J. Physiol. Gastrointest. Liver Physiol. │ 278 (4),G563-G569 (共著)
131.	2000/02	Recycling of AQP2 occurs through a temperature- and bafilomycin-sensitive trans-Golgi-associated compartment. │ Am. J. Physiol. Renal Physiol. │ 278 (2),F317-F326 (共著)
132.	1999/07	Inhibitory effect of KW-3902, an adenosine A1 receptor antagonist, on p-aminohippurate transport in OK cells. │ Biochim. Biophys. Acta │ 1419 (2),164-172 (共著)
133.	1999/07	Transport characteristics of diphenhydramine in human intestinal epithelial Caco-2 cells: contribution of pH-dependent transport system. │ J. Pharmacol. Exp. Ther. │ 290 (1),388-392 (共著)
134.	1998/10	Vasopressin regulated trafficking of a green fluorescent protein-aquaporin 2 chimera in LLC-PK1 cells. │ Histochem. Cell Biol. │ 110 (4),377-386 (共著)
135.	1998/09	Cellular mechanisms of aquaporin trafficking. │ Am. J. Physiol. │ 275 (3),F328-F331 (共著)
136.	1997/06	Protein kinase A phosphorylation is involved in regulated exocytosis of aquaporin-2 in transfected LLC-PK1 cells. │ Am. J. Physiol. │ 272 (6 Pt 2),F817-F822 (共著)
137.	1996/03	Direct demonstration of aquaporin-2 water channel recycling in stably transfected LLC-PK1 epithelial cells. │ Am. J. Physiol. │ 270 (3 Pt 2),F548-F553 (共著)
138.	1995/08	Constitutive and regulated membrane expression of aquaporin 1 and aquaporin 2 water channels in stably transfected LLC-PK1 epithelial cells. │ Proc. Natl. Acad. Sci. U.S.A. │ 92 (16),7212-7216 (共著)
139.	1995/07	Cellular distribution of the aquaporins: a family of water channel proteins. │ Histochem. Cell Biol. │ 104 (1),1-9 (共著)
140.	1995/03	Identification of organic cation transporter in rat renal brush-border membrane by photoaffinity labeling. │ Biol. Pharm. Bull. │ 18 (3),388-395 (共著)
141.	1995/02	The AQP2 water channel: effect of vasopressin treatment, microtubule disruption, and distribution in neonatal rats. │ J. Membr. Biol. │ 143 (3),165-175 (共著)
142.	1994/03	Bestatin transport in rabbit intestinal brush-border membrane vesicles. │ Biochem. Pharmacol. │ 47 (6),1089-1090 (共著)
143.	1993/09	Transport mechanism of choline in rat renal brush-border membrane. │ Biol. Pharm. Bull. │ 16 (9),889-894 (共著)
144.	1993/05	Transport of bestatin in rat renal brush-border membrane vesicles. │ Biochem. Pharmacol. │ 45 (9),1763-1768 (共著)
145.	1993/03	Characteristics of organic cation transporter in rat renal basolateral membrane. │ Biochim. Biophys. Acta │ 1146 (2),197-202 (共著)
146.	1992/04	Expression of renal organic cation transporter in Xenopus laevis oocytes. │ Biochem. J. │ 283 (Pt 2),409-411 (共著)
147.	1992/02	H+ coupled active transport of bestatin via the dipeptide transport system in rabbit intestinal brush-border membranes. │ J. Pharmacol. Exp. Ther. │ 260 (2),482-486 (共著)
148.	1991/11	Trans-stimulation effect on H+-organic cation antiport system in rat renal brush-border membranes. │ Am. J. Physiol. │ 261 (5 Pt 2),F774-F778 (共著)
149.	1990/02	Transport mechanisms of bestatin in rabbit intestinal brush-border membranes: role of H+/dipeptide cotransport system. │ J. Pharmacol. Exp. Ther. │ 252 (2),859-862 (共著)
150.	1989/07	Inhibitory effect of diethyl pyrocarbonate on the H+/organic cation antiport system in rat renal brush-border membranes. │ J. Biol. Chem. │ 264 (21),12232-12237 (共著)